KynderMed will leverage new and proprietary insights into helping reduce the incidence of preterm births resulting from the reduction of melatonin.

Helping them

 

We have developed the product, validated the technology in two small human trials, held an informal meeting with the FDA who are quite supportive, created a world class leadership team, secured a manufacturer and locked in a favorable product cost, and developed a detailed roadmap to market

 

All that remains to gain FDA approval is a few tweaks to the sleep mask and small pivotal clinical trial

 

KynderMed is currently raising the requisite funding to take the  KynderMed solution through the final FDA approval process.

 

If you are a qualified investor and have an interest in learning more, please contact:

 

Don Rosenkoetter

Executive Chairman

gdr@kyndermed.com

(617) 461 6654